PMID- 19190769
OWN - NLM
STAT- MEDLINE
DCOM- 20090318
LR  - 20211020
IS  - 1740-2530 (Electronic)
IS  - 1740-2522 (Print)
IS  - 1740-2522 (Linking)
VI  - 2008
DP  - 2008
TI  - Physiological role of plasmacytoid dendritic cells and their potential use in 
      cancer immunity.
PG  - 106321
LID - 10.1155/2008/106321 [doi]
LID - 106321
AB  - Dendritic cells (DCs) play a pivotal role in the control of innate and adaptive 
      immune responses. They are a heterogeneous cell population, where plasmacytoid 
      dendritic cells (pDCs) are a unique subset capable of secreting high levels of 
      type I IFNs. It has been demonstrated that pDCs can coordinate events during the 
      course of viral infection, atopy, autoimmune diseases, and cancer. Therefore, 
      pDC, as a main source of type I IFN, is an attractive target for therapeutic 
      manipulations of the immune system to elicit a powerful immune response against 
      tumor antigens in combination with other therapies. The therapeutic vaccination 
      with antigen-pulsed DCs has shown a limited efficacy to generate an effective 
      long-lasting immune response against tumor cells. A rational manipulation and 
      design of vaccines which could include DC subsets outside "Langerhans cell 
      paradigm" might allow us to improve the therapeutic approaches for cancer 
      patients.
FAU - Schettini, Jorge
AU  - Schettini J
AD  - Department of Immunology, Mayo Clinic College of Medicine, Mayo Clinic Arizona, 
      13400 E. Shea Blvd, Scottsdale, AZ 85259, USA.
FAU - Mukherjee, Pinku
AU  - Mukherjee P
LA  - eng
GR  - P50 CA102701/CA/NCI NIH HHS/United States
GR  - P50 CA 102701/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20090126
PL  - Egypt
TA  - Clin Dev Immunol
JT  - Clinical & developmental immunology
JID - 101183692
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Interferon Type I)
SB  - IM
MH  - Animals
MH  - Antigen Presentation/immunology
MH  - Antigens, Neoplasm/*immunology/metabolism
MH  - Cancer Vaccines/*immunology/therapeutic use
MH  - Cell Differentiation/immunology
MH  - Cell Movement
MH  - Dendritic Cells/*immunology/metabolism/pathology
MH  - Gene Expression Regulation/immunology
MH  - Humans
MH  - Immunity, Cellular
MH  - Interferon Type I/immunology/*metabolism
MH  - Neoplasms/*immunology/pathology/*therapy
PMC - PMC2630490
EDAT- 2009/02/05 09:00
MHDA- 2009/03/19 09:00
PMCR- 2009/01/26
CRDT- 2009/02/05 09:00
PHST- 2008/08/20 00:00 [received]
PHST- 2008/10/12 00:00 [accepted]
PHST- 2009/02/05 09:00 [entrez]
PHST- 2009/02/05 09:00 [pubmed]
PHST- 2009/03/19 09:00 [medline]
PHST- 2009/01/26 00:00 [pmc-release]
AID - 10.1155/2008/106321 [doi]
PST - ppublish
SO  - Clin Dev Immunol. 2008;2008:106321. doi: 10.1155/2008/106321. Epub 2009 Jan 26.